Whitepaper: BioFire® mycoplasma solution: results in one hour, fully automated detection system
Posted: 25 June 2020 | bioMérieux | No comments yet
In this whitepaper, bioMérieux describe the potential application of BioFire® FilmArray technology – a well-recognised technology used in infectious disease diagnostics – for rapid at-line detection of mycoplasmas in the pharmaceutical industry.
Routine testing for microbial contaminants is critically required in biopharmaceutical manufacturing to maintain control over product quality, safety and efficacy. In this whitepaper, we describe the potential application of BioFire® FilmArray technology – a well-recognised technology used in infectious disease diagnostics – for rapid at-line detection of mycoplasmas in the pharmaceutical industry.1
Related content from this organisation
- European Pharmaceutical Review Issue 4 2024
- Application note: Automated nucleic acid amplification assay for mycoplasma detection in cell and gene therapy products
- Next-Generation Rapid mRNA Vaccine CQA Analytics
- Application note: Role of in-house isolates in pharmaceutical quality control
- Application note: Low Endotoxin Recovery case study
Issue
Related topics
Cell culture automation, Manufacturing, Rapid Microbiological Methods (RMMs), Technology
